Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

33
Real-time Quote. Real-time Tradegate - 01/27 07:24:54 am
76.115 EUR   +1.03%
01/08 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
2014 MORPHOSYS : AG: Corporate Calendar 2015
2014 MORPHOSYS : Announces Clinical Milestone in Oncology Program
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
01/20/2015 01/21/2015 01/22/2015 01/23/2015 01/26/2015 Date
74.6(c) 73.78(c) 74.26(c) 75.35(c) 75.34(c) Last
102 012 168 873 163 271 121 704 84 170 Volume
-0.81% -1.10% +0.65% +1.47% -0.01% Change
More quotes
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 63,3 M
EBIT 2014 -7,78 M
Net income 2014 -5,83 M
Finance 2014 200 M
Yield 2014 -
Sales 2015 65,7 M
EBIT 2015 -17,4 M
Net income 2015 -15,9 M
Finance 2015 194 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 28,3x
EV / Sales 2015 27,4x
Capitalization 1 993 M
More Financials
Latest news on MORPHOSYS AG
01/08 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
2014 MORPHOSYS : AG: Corporate Calendar 2015
2014 MORPHOSYS : Announces Clinical Milestone in Oncology Program
2014 MORPHOSYS : and Xencor Report Final Results from Phase 1/2a Trial of Mor208
2014 MORPHOSYS : MOR208 Program Receives Positive Opinion for Orphan Medicinal Produc..
2014 MORPHOSYS : Partner Roche Provides Update on Trial of Gantenerumab in Prodromal ..
2014 MORPHOSYS : Partner Roche Provides Update on Trial of Gantenerumab in Prodromal ..
2014 MORPHOSYS : MOR208 Program Receives Positive Opinion for Orphan Medicinal Produc..
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF